BS_NPQJ20KX
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 6.110381077529566
- age_years
- 7.915
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.435
- COAGULATION+0.394
- KRAS_SIGNALING_DN+0.389
- TNFA_SIGNALING_VIA_NFKB+0.373
- INFLAMMATORY_RESPONSE+0.349
- IL6_JAK_STAT3_SIGNALING+0.299
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.296
- APICAL_SURFACE+0.292
- P53_PATHWAY+0.271
- ANGIOGENESIS+0.254
Top 10 suppressed
- MYC_TARGETS_V1-0.699
- E2F_TARGETS-0.643
- G2M_CHECKPOINT-0.615
- OXIDATIVE_PHOSPHORYLATION-0.571
- PROTEIN_SECRETION-0.499
- UNFOLDED_PROTEIN_RESPONSE-0.468
- MTORC1_SIGNALING-0.458
- MYC_TARGETS_V2-0.448
- DNA_REPAIR-0.425
- MITOTIC_SPINDLE-0.339
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2689710 | — | — | 0.943 |
| 2 | TCGA-55-8619-01A-11R-2403-07 | — | cohortA1 | 0.937 |
| 3 | BS_R244Z0WX | pilocytic astrocytoma | — | 0.933 |
| 4 | BS_NQB91P48 | pilocytic astrocytoma | — | 0.932 |
| 5 | TCGA-99-AA5R-01A-11R-A39D-07 | — | cohortA1 | 0.929 |
| 6 | TCGA-A2-A0CO-01A-13R-A22K-07 | — | A | 0.926 |
| 7 | c5e09ad2-1f0b-4ea3-9565-a1664f1bb468 | — | — | 0.925 |
| 8 | TCGA-GM-A4E0-01A-12R-A266-07 | — | A | 0.924 |
| 9 | SRR1440082 | GTEX | — | 0.924 |
| 10 | TCGA-GM-A3XN-01A-12R-A22U-07 | — | A | 0.924 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.435 | Inavolisib | — uncovered |
| COAGULATION | 0.394 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.389 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.373 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.349 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.299 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.296 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.292 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.271 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.254 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| HYPOXIA | 0.246 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.234 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.233 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.228 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.224 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.222 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.193 | Idelalisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.163 | Inavolisib | — uncovered |